CNTY-101
CNTY-101-111-01 (ELiPSE-1)
Phase 1 mab terminated
Quick answer
CNTY-101 for R/R CD19-Positive B-Cell Malignancies is a Phase 1 program (mab) at Century Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Century Therapeutics
- Indication
- R/R CD19-Positive B-Cell Malignancies
- Phase
- Phase 1
- Modality
- mab
- Status
- terminated